Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 311

1.
2.

The role of sildenafil in the development of transplant arteriosclerosis in rat aortic grafts.

Luo S, Yang M, Jin H, Xu ZQ, Li YF, Xia P, Yang YR, Chen BC, Zhang Y.

Am J Transl Res. 2017 Nov 15;9(11):4914-4924. eCollection 2017.

3.

Inhibition of nitric oxide synthase unmasks vigorous vasoconstriction in established pulmonary arterial hypertension.

Tanaka M, Abe K, Oka M, Saku K, Yoshida K, Ishikawa T, McMurtry IF, Sunagawa K, Hoka S, Tsutsui H.

Physiol Rep. 2017 Dec;5(23). pii: e13537. doi: 10.14814/phy2.13537.

4.

Drug repurposing for the treatment of glioblastoma multiforme.

Abbruzzese C, Matteoni S, Signore M, Cardone L, Nath K, Glickson JD, Paggi MG.

J Exp Clin Cancer Res. 2017 Nov 28;36(1):169. doi: 10.1186/s13046-017-0642-x. Review.

5.

Incidence and risk of respiratory tract infection associated with specific drug therapy in pulmonary arterial hypertension: a systematic review.

Gu Z, Zhang C, Wei A, Cui M, Pu J, Lin H, Liu X.

Sci Rep. 2017 Nov 24;7(1):16218. doi: 10.1038/s41598-017-16349-7.

6.

Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension.

de Mendonça L, Felix NS, Blanco NG, Da Silva JS, Ferreira TP, Abreu SC, Cruz FF, Rocha N, Silva PM, Martins V, Capelozzi VL, Zapata-Sudo G, Rocco PRM, Silva PL.

Stem Cell Res Ther. 2017 Oct 3;8(1):220. doi: 10.1186/s13287-017-0669-0.

7.

Pulmonary hypertension: diagnosis, imaging techniques, and novel therapies.

Goldberg AB, Mazur W, Kalra DK.

Cardiovasc Diagn Ther. 2017 Aug;7(4):405-417. doi: 10.21037/cdt.2017.04.11. Review.

8.

Regulation of Pulmonary Vascular Smooth Muscle Contractility in Pulmonary Arterial Hypertension: Implications for Therapy.

Lyle MA, Davis JP, Brozovich FV.

Front Physiol. 2017 Aug 23;8:614. doi: 10.3389/fphys.2017.00614. eCollection 2017. Review.

9.

Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.

Vizza CD, Jansa P, Teal S, Dombi T, Zhou D.

BMC Cardiovasc Disord. 2017 Sep 6;17(1):239. doi: 10.1186/s12872-017-0674-3.

10.

Association between oral sildenafil dosing, predicted exposure, and systemic hypotension in hospitalised infants.

Hornik CP, Onufrak NJ, Smith PB, Cohen-Wolkowiez M, Laughon MM, Clark RH, Gonzalez D.

Cardiol Young. 2018 Jan;28(1):85-92. doi: 10.1017/S1047951117001639. Epub 2017 Aug 8.

11.

Retrospective evaluation of pimobendan and sildenafil therapy for severe pulmonary hypertension due to lung disease and hypoxia in 28 dogs (2007-2013).

Murphy LA, Russell N, Bianco D, Nakamura RK.

Vet Med Sci. 2017 Mar 8;3(2):99-106. doi: 10.1002/vms3.60. eCollection 2017 May.

12.

Challenges in the development of chronic pulmonary hypertension models in large animals.

Rothman A, Wiencek RG, Davidson S, Evans WN, Restrepo H, Sarukhanov V, Mann D.

Pulm Circ. 2017 Feb 1;7(1):156-166. doi: 10.1086/690099. eCollection 2017 Mar.

13.

A Novel Therapeutic Approach in the Treatment of Pulmonary Arterial Hypertension: Allium ursinum Liophylisate Alleviates Symptoms Comparably to Sildenafil.

Bombicz M, Priksz D, Varga B, Kurucz A, Kertész A, Takacs A, Posa A, Kiss R, Szilvassy Z, Juhasz B.

Int J Mol Sci. 2017 Jul 4;18(7). pii: E1436. doi: 10.3390/ijms18071436.

14.

Severe pulmonary arterial hypertension associated with congenital cardiac shunts: evolution under specific treatment.

Negoi RI, Ghiorghiu I, Filipoiu F, Hostiuc M, Negoi I, Ginghina C.

J Med Life. 2017 Apr-Jun;10(2):131-138.

15.

Identifying "super responders" in pulmonary arterial hypertension.

Halliday SJ, Hemnes AR.

Pulm Circ. 2017 Apr-Jun;7(2):300-311. doi: 10.1177/2045893217697708. Epub 2017 May 30.

16.

Sex differences in pulmonary vascular control: focus on the nitric oxide pathway.

de Wijs-Meijler DPM, Danser AHJ, Reiss IKM, Duncker DJ, Merkus D.

Physiol Rep. 2017 Jun;5(11). pii: e13200. doi: 10.14814/phy2.13200.

17.

Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliation.

Goldberg DJ, Zak V, Goldstein BH, Chen S, Hamstra MS, Radojewski EA, Maunsell E, Mital S, Menon SC, Schumacher KR, Payne RM, Stylianou M, Kaltman JR, deVries TM, Yeager JL, Paridon SM; Pediatric Heart Network Investigators.

Am Heart J. 2017 Jun;188:42-52. doi: 10.1016/j.ahj.2017.02.030. Epub 2017 Mar 6.

PMID:
28577680
18.

Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials.

Gao XF, Zhang JJ, Jiang XM, Ge Z, Wang ZM, Li B, Mao WX, Chen SL.

Patient Prefer Adherence. 2017 May 8;11:871-885. doi: 10.2147/PPA.S133288. eCollection 2017.

19.

Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.

Lian TY, Jiang X, Jing ZC.

Drug Des Devel Ther. 2017 Apr 13;11:1195-1207. doi: 10.2147/DDDT.S117277. eCollection 2017. Review.

20.

The effect of PDE5 inhibitors on bone and oxidative damage in ovariectomy-induced osteoporosis.

Alp HH, Huyut Z, Yildirim S, Başbugan Y, Ediz L, Şekeroğlu MR.

Exp Biol Med (Maywood). 2017 May;242(10):1051-1061. doi: 10.1177/1535370217703352. Epub 2017 Apr 11.

Supplemental Content

Support Center